Gelber RD, Wang XV, Cole BF, Cameron D, et al. Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY Eur J Cancer 2022;166:219-228.
PMID: 35313167